S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
ASX:GTG

Genetic Technologies Limited (GTG.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 8412 7000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9,864.00
Book ValueA$0.00 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive GTG News and Ratings via Email

Sign-up to receive the latest news and ratings for GTG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genetic Technologies Limited (GTG.AX) (ASX:GTG) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Technologies Limited (GTG.AX)?

Wall Street analysts have given Genetic Technologies Limited (GTG.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genetic Technologies Limited (GTG.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Genetic Technologies Limited (GTG.AX)'s key competitors?

What other stocks do shareholders of Genetic Technologies Limited (GTG.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies Limited (GTG.AX) investors own include Viralytics (VRACY) and Orthocell Limited (OCC.AX) (OCC).

Who are Genetic Technologies Limited (GTG.AX)'s key executives?

Genetic Technologies Limited (GTG.AX)'s management team includes the following people:
  • Dr. Jerzy Muchnicki MBBS, Interim CEO & Exec. Director (Age 63, Pay $153.11k)
  • Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA, Chief Financial Officer (Age 59)
  • Mr. Stanley Sack, Chief Operating Officer (Age 56, Pay $318.28k)
  • Dr. Richard Allman, Chief Scientific Officer (Age 60, Pay $188.21k)
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, Consultant
  • Mr. Justyn Stedwell, Company Sec. (Age 39)

What is Genetic Technologies Limited (GTG.AX)'s stock symbol?

Genetic Technologies Limited (GTG.AX) trades on the ASX under the ticker symbol "GTG."

How big of a company is Genetic Technologies Limited (GTG.AX)?

Genetic Technologies Limited (GTG.AX) has a market capitalization of $0.00 and generates $9,864.00 in revenue each year.

What is Genetic Technologies Limited (GTG.AX)'s official website?

The official website for Genetic Technologies Limited (GTG.AX) is www.gtglabs.com.

How can I contact Genetic Technologies Limited (GTG.AX)?

The company can be reached via phone at 61 3 8412 7000.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.